Royalty Pharma
Royalty Pharma plc, headquartered in the United States, is a leading player in the biopharmaceutical industry, specialising in the acquisition of revenue-generating pharmaceutical royalties. Founded in 1996, the company has established itself as a pioneer in the royalty financing model, enabling innovation in drug development while providing capital to biopharmaceutical companies. With a diverse portfolio that includes royalties from some of the world's most successful therapies, Royalty Pharma stands out for its unique approach to funding and supporting drug development. The company operates primarily in North America and Europe, positioning itself as a key partner in the life sciences sector. Notable achievements include a robust market presence and a commitment to advancing healthcare through strategic investments in transformative therapies.
DitchCarbon Score
How does Royalty Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Royalty Pharma's score of 35 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Royalty Pharma's reported carbon emissions
In 2024, Royalty Pharma reported approximately 23,266,000 kg CO2e in Scope 3 emissions, specifically from investments. This figure represents a decrease from the previous year's emissions of about 32,002,000 kg CO2e in 2023. The company has consistently disclosed its Scope 3 emissions, which are the only emissions reported, as there is no data available for Scope 1 and Scope 2 emissions. Over the past few years, Royalty Pharma's Scope 3 emissions have shown a downward trend, with emissions recorded at about 19,610,000 kg CO2e in 2022 and approximately 18,445,000 kg CO2e in 2021. Despite this positive trajectory, the company has not set specific reduction targets or initiatives, nor does it participate in the Science Based Targets initiative (SBTi) or other formal climate pledges. Royalty Pharma's emissions data is not cascaded from any parent organisation, and all reported figures are derived directly from the company itself. The organisation's commitment to addressing climate change remains evident through its transparency in emissions reporting, although further commitments or reduction strategies have yet to be established.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | 18,445,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Royalty Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
